Insmed buys AstraZeneca's respiratory drug for $150M: 5 things to know

Insmed, a Bridgewater, N.J.-based drugmaker focusing on treatments for rare diseases, purchased the exclusive global rights to AstraZeneca's experimental respiratory drug AZD7986.

Here are five things to know about the deal.

  1. AstraZeneca, based in London, will receive an upfront payment of $30 million and up to $120 million in future payments related to clinical, regulatory and sales-related milestones.

  2. AstraZeneca also maintains the option to negotiate a deal with Insmed to develop AZD7986 for the treatment of chronic obstructive pulmonary disease or asthma.

  3. AZD7986 was developed to inhibit an enzyme that plays a key role in inflammatory diseases.

  4. Insmed said it will conduct a mid-stage study of AZD7986 in non-cystic fibrosis bronchiectasis, which causes permanently dilated airways in the lungs due to chronic inflammation and infection, reported Reuters.

  5. The deal comes just two days after AstraZeneca sold the rights to an experimental anti-inflammatory drug to Parsippany-Troy Hills, N.J.-based Allergan for $250 million.

More articles on supply chain:

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars